Mental Health Bulletin, July 2008 s2

Gynaecologic Oncology May 2016

This bulletin covers aspects of gynaecological cancers and should be of interest to multidisciplinary teams working in this area.

Sections can include:  Combined Modality Therapies  Drug Therapy  Pathology, Staging, Polymorphisms & Biomarkers  Prognosis, Survival & Risk Factors  Radiotherapy & Imaging  Supportive Care & Symptom Management  Surgery

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by: Kirsty Coltart Subject Librarian Beatson West of Scotland Cancer Centre 0141 301 7285, [email protected]

1 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network General

Bookman, M.A. (2016). Optimal primary therapy of ovarian cancer. Annals of Oncology 27,Suppl 1:58-62.

Ebell, M.H., Culp, M.B. and Radke, T.J. (2016). A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. American Journal of Preventive Medicine 50,3:384-394.

Morice, P., Leary, A., Creutzberg, C., et al. (2016). Endometrial cancer. Lancet 387,10023:1094-1108.

Narod, S. (2016). Can advanced-stage ovarian cancer be cured? Nature Reviews Clinical Oncology 13,4:255-261.

Pelkofski, E., Stine, J., Wages, N.A., et al. (2016). Cervical Cancer in Women Aged 35 Years and Younger. Clinical therapeutics 38,3:459-466.

Xu, Y., Hanna, R.K. and Elshaikh, M.A. (2016). Adjuvant therapy of uterine clear cell carcinoma: a review. Archives of Gynecology & Obstetrics 293,3:485-492.

Combined Modality Therapies

Corrado, G., Cutillo, G., Saltari, M., et al. (2016). Surgical and Oncological Outcome of Robotic Surgery Compared With Laparoscopic and Abdominal Surgery in the Management of Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy. International Journal of Gynecological Cancer 26,3:539-546.

de Azevedo,Carla Rameri Alexandre Silva, Thuler, L.C.S., de Mello, M.J.G., et al. (2016). Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review. International Journal of Gynecological Cancer 26,4:729-736.

Fagotti, A., Ferrandina, G., Vizzielli, G., et al. (2016). Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. European journal of cancer 59,22-33.

Grabowski, J.P., Harter, P., Heitz, F., et al. (2016). Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecologic oncology 140,3:457-462.

Kirchheiner, K., Potter, R., Tanderup, K., et al. (2016). Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. International journal of radiation oncology, biology, physics 94,5:1088-1098.

Mueller, J.J., Zhou, Q.C., Iasonos, A., et al. (2016). Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic oncology 140,3:436-442.

Petrillo, M., De Iaco, P., Cianci, S., et al. (2016). Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Annals of Surgical Oncology 23,5:1660-1665. 2 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Drug & Targeted Therapy

Bogliolo, S., Gardella, B., Dominoni, M., et al. (2016). Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. Archives of Gynecology & Obstetrics 293,4:701-708.

Chan, J.K., Brady, M.F., Penson, R.T., et al. (2016). Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine 374,8:738-748.

Crafton, S.M. and Salani, R. (2016). Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer. Clinical therapeutics 38,3:449-458.

El-Husseiny, K., Motawei, H. and Ali, M.S. (2016). Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. International Journal of Gynecological Cancer 26,3:437-442.

Emons, G., Kurzeder, C., Schmalfeldt, B., et al. (2016). Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecologic oncology 140,3:450-456.

HIS. Response to NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. (April 2016)

Hotouras, A., Desai, D., Bhan, C., et al. (2016). Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review. International Journal of Gynecological Cancer 26,4:661-670.

Ledermann, J.A., Embleton, A.C., Raja, F., et al. (2016). Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 387,10023:1066-1074.

Marchetti, C., De Felice, F., Palaia, I., et al. (2016). Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. Oncotarget 7,11:13221-13227.

Monk, B.J., Minion, L.E. and Coleman, R.L. (2016). Anti-angiogenic agents in ovarian cancer: past, present, and future. Annals of Oncology 27,Suppl 1:33-39.

NICE. TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. (April 2016)

Pujade-Lauraine, E., Selle, F., Weber, B., et al. (2016). Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. Journal of Clinical Oncology 34,7:706-713.

Wallace, S.K., Lin, J.F., Cliby, W.A., et al. (2016). Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study. Journal of the National Comprehensive Cancer Network 14,5:539-550.

Woopen, H., Richter, R., Ismaeel, F., et al. (2016). The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecologic oncology 140,3:554-558.

3 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Pathology, Staging, Polymorphisms & Biomarkers

Bakhsh, S., Kinloch, M., Hoang, L.N., et al. (2016). Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology 68,6:916-924.

Emens, L.A., Kok, M. and Ojalvo, L.S. (2016). Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Current opinion in obstetrics & gynecology 28,2:142- 147.

Friedlander, M.L., Russell, K., Millis, S., et al. (2016). Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. International Journal of Gynecological Cancer 26,4:648-654.

Fujiwara, K., Shintani, D. and Nishikawa, T. (2016). Clear-cell carcinoma of the ovary. Annals of Oncology 27,Suppl 1:50-52.

Hansen, J.M., Coleman, R.L. and Sood, A.K. (2016). Targeting the tumour microenvironment in ovarian cancer. European journal of cancer 56,131-143.

Hope, E.R., Mhawech-Fauceglia, P., Pejovic, T., et al. (2016). Nestin: A biomarker of aggressive uterine cancers. Gynecologic oncology 140,3:503-511.

Kurosaki, A., Hasegawa, K., Kato, T., et al. (2016). Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression. International Journal of Cancer 138,8:1994-2002.

Ledermann, J.A. (2016). PARP inhibitors in ovarian cancer. Annals of Oncology 27,Suppl 1:40-44.

Lim, A.W.W., Hamilton, W., Hollingworth, A., et al. (2016). Performance characteristics of visualising the cervix in symptomatic young females: a review of primary care records in females with and without cervical cancer. British Journal of General Practice 66,644:e189- 92.

Lim, A., Mesher, D., Gentry-Maharaj, A., et al. (2016). Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG: An International Journal of Obstetrics & Gynaecology 123,6:1012-1020.

Meys, E.M.J., Kaijser, J., Kruitwagen, R.F.P.M., et al. (2016). Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. European journal of cancer 58,17-29.

Norquist, B.M., Harrell, M.I., Brady, M.F., et al. (2016). Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncology 2,4:482-490.

Penson, R.T., Sales, E., Sullivan, L., et al. (2016). A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecologic oncology 141,1:108-112.

Perren, T.J. (2016). Mucinous epithelial ovarian carcinoma. Annals of Oncology 27,Suppl 1:53-57.

Ratnavelu, N.D.G., Brown, A.P., Mallett, S., et al. (2016). Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database of Systematic Reviews 3,010360.

4 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Rodriguez-Rodriguez, L., Hirshfield, K.M., Rojas, V., et al. (2016). Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. Gynecologic oncology 141,1:2-9.

Wang, L.Q., Zhao, W.D., Jiao, X.J., et al. (2016). Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status in ovarian cancer. European journal of gynaecological oncology 37,2:204-210.

Prognosis, Survival & Risk Factors

Bernardini, M.Q., Gien, L.T., Lau, S., et al. (2016). Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecologic oncology 141,1:148-154.

Elit, L., Kennedy, E.B., Fyles, A., et al. (2016). Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update. Current Oncology 23,2:109-118.

Friedlander, M., Mercieca-Bebber, R.L. and King, M.T. (2016). Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Annals of Oncology 27,Suppl 1:66-71.

Matsuo, K., Fullerton, M.E. and Moeini, A. (2016). Treatment patterns and survival outcomes in patients with cervical cancer complicated by complete uterine prolapse: a systematic review of literature. International Urogynecology Journal 27,1:29-38.

Praestegaard, C., Kjaer, S.K., Nielsen, T.S.S., et al. (2016). The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology 41,71-79.

Radiotherapy & Imaging

Bourgioti, C., Chatoupis, K. and Moulopoulos, L.A. (2016). Current imaging strategies for the evaluation of uterine cervical cancer. World Journal of Radiology 8,4:342-354.

Jiang, Z.H., Li, K.T., Tian, J.W., et al. (2016). An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors. Archives of Gynecology & Obstetrics 293,2:303-310.

Mazeron, R., Petit, C., Rivin, E., et al. (2016). 45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims?. Clinical Oncology (Royal College of Radiologists) 28,3:171-177.

Sharma, A., Burnell, M., Gentry-Maharaj, A., et al. (2016). Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics & Gynecology 47,2:228-235.

Susko, M., Craciunescu, O., Meltsner, S., et al. (2016). Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy. International journal of radiation oncology, biology, physics 94,5:1099-1105.

5 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network van Nagell, J.R.J. and Miller, R.W. (2016). Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. Obstetrics & Gynecology 127,5:848-858.

Supportive Care & Symptom Management

Bergin, R.J., Grogan, S.M., Bernshaw, D., et al. (2016). Developing an Evidence-Based, Nurse-Led Psychoeducational Intervention With Peer Support in Gynecologic Oncology. Cancer nursing 39,2:E19-30.

Correa, C.S.L., Leite, I.C.G., Andrade, A.P.S., et al. (2016). Sexual function of women surviving cervical cancer. Archives of Gynecology & Obstetrics 293,5:1053-1063.

Donovan, H.S., Hagan, T.L., Campbell, G.B., et al. (2016). Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. Supportive Care in Cancer 24,6:2635- 2642.

Klafke, N., Mahler, C., von Hagens, C., et al. (2016). Developing and implementing a complex Complementary and Alternative (CAM) nursing intervention for breast and gynecologic cancer patients undergoing chemotherapy-report from the CONGO (complementary nursing in gynecologic oncology) study. Supportive Care in Cancer 24,5:2341-2350.

Li, J., Huang, J., Zhang, J., et al. (2016). A home-based, nurse-led health program for postoperative patients with early-stage cervical cancer: A randomized controlled trial. European Journal of Oncology Nursing 21,174-180.

Long, D., Friedrich-Nel, H.S. and Joubert, G. (2016). Patients' informational needs while undergoing brachytherapy for cervical cancer. International Journal for Quality in Health Care 28,2:200-208.

Merk, B.A., Havrilesky, L.J., Ehrisman, J.A., et al. (2016). Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. Current Medical Research & Opinion 32,3:453-458.

Morris, M., Friedemann Smith, C., Boxell, E., et al. (2016). Quantitative evaluation of an information leaflet to increase prompt help-seeking for gynaecological cancer symptoms. BMC Public Health 16,1:374.

Surgery

Bendifallah, S., Nikpayam, M., Ballester, M., et al. (2016). New Pointers for Surgical Staging of Borderline Ovarian Tumors. Annals of Surgical Oncology 23,2:443-449.

Greggi, S., Falcone, F., Carputo, R., et al. (2016). Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Gynecologic oncology 140,3:425- 429.

Gueli Alletti, S., Bottoni, C., Fanfani, F., et al. (2016). Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. American Journal of Obstetrics & Gynecology 214,4:503.e1-503.e6.

6 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network Herling, S.F., Palle, C., Moeller, A.M., et al. (2016). The Experience of Robotic-Assisted Laparoscopic Hysterectomy for Women Treated for Early-Stage Endometrial Cancer: A Qualitative Study. Cancer nursing 39,2:125-133.

Luchini, C., Nottegar, A., Solmi, M., et al. (2016). Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. Surgical oncology 25,1:60-65.

Minig, L., Padilla Iserte, P., Zorrero, C., et al. (2016). Robotic Surgery in Women With Ovarian Cancer: Surgical Technique and Evidence of Clinical Outcomes. Journal of Minimally Invasive Gynecology 23,3:309-316.

Uccella, S., Bonzini, M., Palomba, S., et al. (2016). Laparoscopic vs. open treatment of endometrial cancer in the elderly and very elderly: An age-stratified multicenter study on 1606 women. Gynecologic oncology 141,2:211-217.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin. Sources used for this bulletin: OVID databases, SIGN, NICE, Healthcare Improvement Scotland

7 Gynaecologic Oncology, May 2016 Kirsty Coltart, Subject Librarian, NHSGGC Library Network